Novartis has received further approval from the US FDA to produce radioligand therapy Pluvicto. In the future, Pluvicto cans will be manufactured in a modern 70,000-square-foot facility at the Indianapolis site, as Novartis announced Friday
Pluvicto is used to treat prostate cancer and Novartis plans to significantly expand production of this therapy to meet high global demand. The plant in the state of Indiana is the second in the US and production also takes place in Italy and Spain. Factories are also planned in Japan and China, the report said.
In 2024 and beyond, Novartis plans to increase Pluvicto production capacity to up to 250,000 doses per year. The therapy has blockbuster potential. In the third quarter alone, Novartis generated nearly $260 million in revenue from sales of Pluvicto. (sda/awp)
Soource :Watson
I am Amelia James, a passionate journalist with a deep-rooted interest in current affairs. I have more than five years of experience in the media industry, working both as an author and editor for 24 Instant News. My main focus lies in international news, particularly regional conflicts and political issues around the world.
